Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.

@article{Kwiatkowski2004IronCT,
  title={Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.},
  author={Janet L. Kwiatkowski and Alan R Cohen},
  journal={Hematology/oncology clinics of North America},
  year={2004},
  volume={18 6},
  pages={1355-77, ix}
}
Regular red cell transfusion therapy may be life-saving or may reduce complications substantially in several hematological disorders. The inevitable consequence of repeated transfusions is iron loading, which, if untreated, leads to organ failure and death. Chelation therapy with deferoxamine is the standard of care for patients who have transfusional iron overload. The necessity to administer this drug parenterally limits compliance; this has prompted the search for a safe and effective orally… CONTINUE READING